1. Home
  2. TVRD vs RGCO Comparison

TVRD vs RGCO Comparison

Compare TVRD & RGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • RGCO
  • Stock Information
  • Founded
  • TVRD 2017
  • RGCO 1912
  • Country
  • TVRD United States
  • RGCO United States
  • Employees
  • TVRD N/A
  • RGCO N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • RGCO Oil & Gas Production
  • Sector
  • TVRD Health Care
  • RGCO Utilities
  • Exchange
  • TVRD Nasdaq
  • RGCO Nasdaq
  • Market Cap
  • TVRD 246.5M
  • RGCO 219.2M
  • IPO Year
  • TVRD N/A
  • RGCO N/A
  • Fundamental
  • Price
  • TVRD $3.91
  • RGCO $22.50
  • Analyst Decision
  • TVRD Buy
  • RGCO
  • Analyst Count
  • TVRD 7
  • RGCO 0
  • Target Price
  • TVRD $51.67
  • RGCO N/A
  • AVG Volume (30 Days)
  • TVRD 160.8K
  • RGCO 9.3K
  • Earning Date
  • TVRD 11-13-2025
  • RGCO 11-19-2025
  • Dividend Yield
  • TVRD N/A
  • RGCO 3.70%
  • EPS Growth
  • TVRD N/A
  • RGCO 11.26
  • EPS
  • TVRD N/A
  • RGCO 1.29
  • Revenue
  • TVRD N/A
  • RGCO $95,334,212.00
  • Revenue This Year
  • TVRD N/A
  • RGCO $19.22
  • Revenue Next Year
  • TVRD N/A
  • RGCO $2.97
  • P/E Ratio
  • TVRD N/A
  • RGCO $17.41
  • Revenue Growth
  • TVRD N/A
  • RGCO 12.63
  • 52 Week Low
  • TVRD $3.78
  • RGCO $19.06
  • 52 Week High
  • TVRD $43.65
  • RGCO $23.82
  • Technical
  • Relative Strength Index (RSI)
  • TVRD 21.48
  • RGCO 55.39
  • Support Level
  • TVRD $3.78
  • RGCO $20.88
  • Resistance Level
  • TVRD $4.15
  • RGCO $22.07
  • Average True Range (ATR)
  • TVRD 0.31
  • RGCO 0.63
  • MACD
  • TVRD 0.90
  • RGCO 0.15
  • Stochastic Oscillator
  • TVRD 19.40
  • RGCO 59.80

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About RGCO RGC Resources Inc.

RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.

Share on Social Networks: